Castile and Leon to be included in its portfolio Respiratory syncytial virus (RSV) vaccination For children under thirteen months of age who are at potential risk for bronchiolitis. It is estimated that around 13,000 babies will be given a single dose of the vaccine during the next campaign.
According to the date of birth, the birth will be administered in the hospital Since October 1st They receive it at birth; or arrive at people’s health centers around the world between March and September. In addition, infant populations will also be covered, such as premature infants younger than 35 weeks and patients with congenital heart disease, bronchopulmonary dysplasia or other underlying conditions that put them at greater risk of severe RSV bronchiolitis.
This merger also implies a change in the name of the current calendar, From “vaccination” to “lifetime immunization calendar”they reported in a statement from the Ministry of Health.
RSV causes a common viral illness that usually causes mild, cold-like symptoms.but it may result in severe infection In the lower airways and lungs, especially bronchiolitis and pneumonia, especially in infants, but also in the elderly and people with chronic diseases.
RSV can affect people of all ages and is very common in young children, with more than 90% of children infected by the age of 2 years, resulting in a high disease burden in childhood and an overburdened care in childhood. Primary Care in Hospital Nursing During the virus season.
The greatest load is concentrated at under 6 monthsGenerally, RSV infections occur in the fall or winter, so this seasonality means that those born in the fall and winter have the highest rates of hospitalization.
Currently there is a new drug It provides passive immunity against RSV. nirsevimab is a monoclonal antibody (a laboratory-produced molecule intended as a surrogate that can alter or mimic an immune system attack) indicated for the prevention of RSV lower respiratory disease in children under 12 months of age. first season. It has a good safety and efficacy profile and a long half-life, so it provides protection for at least 5 months after administration.
In order to guarantee the new health care provided by the military government of Castile and León, A total of EUR 2,825,680 was invested in this event.